Data Management of Sensitive Human Proteomics Data: Current Practices, Recommendations, and Perspectives for the Future.
Data Management of Sensitive Human Proteomics Data: Current Practices, Recommendations, and Perspectives for the Future.
复制标题
DOI：
10.1016/j.mcpro.2021.100071
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Vizcaíno JA
中科院分区：
文献类型：
--
作者：
Bandeira N;Deutsch EW;Kohlbacher O;Martens L;Vizcaíno JA
Today it is the norm that all relevant proteomics data that support the conclusions in scientific publications are made available in public proteomics data repositories. However, given the increase in the number of clinical proteomics studies, an important emerging topic is the management and dissemination of clinical, and thus potentially sensitive, human proteomics data. Both in the United States and in the European Union, there are legal frameworks protecting the privacy of individuals. Implementing privacy standards for publicly released research data in genomics and transcriptomics has led to processes to control who may access the data, so-called “controlled access” data. In parallel with the technological developments in the field, it is clear that the privacy risks of sharing proteomics data need to be properly assessed and managed. In our view, the proteomics community must be proactive in addressing these issues. Yet a careful balance must be kept. On the one hand, neglecting to address the potential of identifiability in human proteomics data could lead to reputational damage of the field, while on the other hand, erecting barriers to open access to clinical proteomics data will inevitably reduce reuse of proteomics data and could substantially delay critical discoveries in biomedical research. In order to balance these apparently conflicting requirements for data privacy and efficient use and reuse of research efforts through the sharing of clinical proteomics data, development efforts will be needed at different levels including bioinformatics infrastructure, policymaking, and mechanisms of oversight. Availability of proteomics data in public repositories (ProteomeXchange) has become the norm. There are growing ethical issues and legal requirements related to human clinical proteomics data. We review the current state of the art and provide our thoughts about some proteomics data types. We make concrete recommendations to address these issues, summarized in four different points. Availability of proteomics data in the public domain has become the norm, as it has been the case in genomics and transcriptomics for many years. Analogously to sequencing data, there are increasing ethical issues and legal requirements related to sensitive human clinical proteomics data. We review the current state of the art and make concrete recommendations to address these issues in the proteomics field, which are summarized in four different areas.
登录
查看更多内容
影响因子：
14.9
作者：
Ma J;Chen T;Wu S;Yang C;Bai M;Shu K;Li K;Zhang G;Jin Z;He F;Hermjakob H;Zhu Y
通讯作者：
Zhu Y
影响因子：
14.9
作者：
Moriya Y;Kawano S;Okuda S;Watanabe Y;Matsumoto M;Takami T;Kobayashi D;Yamanouchi Y;Araki N;Yoshizawa AC;Tabata T;Iwasaki M;Sugiyama N;Tanaka S;Goto S;Ishihama Y
通讯作者：
Ishihama Y
DOI：
10.1074/mcp.ra120.002359
发表时间：
2021
期刊：
Molecular & cellular proteomics : MCP
影响因子：
--
作者：
Geyer PE;Mann SP;Treit PV;Mann M
通讯作者：
Mann M
影响因子：
14.9
作者：
Papatheodorou, Irene;Moreno, Pablo;Brazma, Alvis
通讯作者：
Brazma, Alvis
影响因子：
56.9
作者：
Gymrek, Melissa;McGuire, Amy L.;Erlich, Yaniv
通讯作者：
Erlich, Yaniv